These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 2099980

  • 21. Localization of the structural domain responsible for the chemotactic properties of thrombin on polymorphonuclear leukocytes.
    Morin A, Arvier MM, Doutremepuich F, Vigneron C.
    Thromb Res; 1990 Oct 01; 60(1):33-42. PubMed ID: 2278036
    [Abstract] [Full Text] [Related]

  • 22. Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs.
    Hoffmann H, Siebeck M, Spannagl M, Weis M, Geiger R, Jochum M, Fritz H.
    Am Rev Respir Dis; 1990 Oct 01; 142(4):782-8. PubMed ID: 2221583
    [Abstract] [Full Text] [Related]

  • 23. Allosteric changes of thrombin catalytic site induced by interaction of bothrojaracin with anion-binding exosites I and II.
    Monteiro RQ, Rapôso JG, Wisner A, Guimarães JA, Bon C, Zingali RB.
    Biochem Biophys Res Commun; 1999 Sep 07; 262(3):819-22. PubMed ID: 10471408
    [Abstract] [Full Text] [Related]

  • 24. Nonpolar interactions of thrombin and its inhibitors at the fibrinogen recognition exosite: thermodynamic analysis.
    Cheng Y, Slon-Usakiewicz JJ, Wang J, Purisima EO, Konishi Y.
    Biochemistry; 1996 Oct 08; 35(40):13021-9. PubMed ID: 8855937
    [Abstract] [Full Text] [Related]

  • 25. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
    Sheffield WP, Eltringham-Smith LJ, Gataiance S, Bhakta V.
    Thromb Haemost; 2009 May 08; 101(5):867-77. PubMed ID: 19404540
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of the thrombin-platelet reaction by hirudin.
    Hoffmann A, Markwardt F.
    Haemostasis; 1984 May 08; 14(2):164-9. PubMed ID: 6735274
    [Abstract] [Full Text] [Related]

  • 27. Human alpha-thrombin inhibition by the highly selective compounds N-ethoxycarbonyl-D-Phe-Pro-alpha-azaLys p-nitrophenyl ester and N-carbobenzoxy-Pro-alpha-azaLys p-nitrophenyl ester: a kinetic, thermodynamic and X-ray crystallographic study.
    De Simone G, Balliano G, Milla P, Gallina C, Giordano C, Tarricone C, Rizzi M, Bolognesi M, Ascenzi P.
    J Mol Biol; 1997 Jun 20; 269(4):558-69. PubMed ID: 9217260
    [Abstract] [Full Text] [Related]

  • 28. Stability of hirudin, a thrombin-specific inhibitor. The structure of alkaline-inactivated hirudin.
    Chang JY.
    J Biol Chem; 1991 Jun 15; 266(17):10839-43. PubMed ID: 2040604
    [Abstract] [Full Text] [Related]

  • 29. Pharmacology of selective thrombin inhibitors.
    Markwardt F.
    Nouv Rev Fr Hematol (1978); 1988 Jun 15; 30(3):161-5. PubMed ID: 3047669
    [Abstract] [Full Text] [Related]

  • 30. Quantitative evaluation of the contribution of ionic interactions to the formation of the thrombin-hirudin complex.
    Stone SR, Dennis S, Hofsteenge J.
    Biochemistry; 1989 Aug 22; 28(17):6857-63. PubMed ID: 2819038
    [Abstract] [Full Text] [Related]

  • 31. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ, Almond HR, Hecker LR, Schott MR, Yabut SC, Zhang HC, Andrade-Gordon P, Corcoran TW, Giardino EC, Kauffman JA, Lewis JM, de Garavilla L, Haertlein BJ, Maryanoff BE.
    J Med Chem; 2005 Mar 24; 48(6):1984-2008. PubMed ID: 15771442
    [Abstract] [Full Text] [Related]

  • 32. Hirudin for diagnostic purposes.
    Stocker K.
    Haemostasis; 1991 Mar 24; 21 Suppl 1():161-7. PubMed ID: 1894191
    [Abstract] [Full Text] [Related]

  • 33. Clinical pharmacology of recombinant hirudin.
    Markwardt F, Nowak G, Stürzebecher J.
    Haemostasis; 1991 Mar 24; 21 Suppl 1():133-6. PubMed ID: 1894188
    [Abstract] [Full Text] [Related]

  • 34. The C-terminal binding domain of hirullin P18. Antithrombin activity and comparison to hirudin peptides.
    Krstenansky JL, Owen TJ, Yates MT, Mao SJ.
    FEBS Lett; 1990 Sep 03; 269(2):425-9. PubMed ID: 2401369
    [Abstract] [Full Text] [Related]

  • 35. Clinico-pharmacological studies with recombinant hirudin.
    Markwardt F, Nowak G, Stürzebecher J, Vogel G.
    Thromb Res; 1988 Dec 01; 52(5):393-400. PubMed ID: 3222782
    [Abstract] [Full Text] [Related]

  • 36. The effect of substituting phosphotyrosine for sulphotyrosine on the activity of hirudin.
    Hofsteenge J, Stone SR, Donella-Deana A, Pinna LA.
    Eur J Biochem; 1990 Feb 22; 188(1):55-9. PubMed ID: 1690647
    [Abstract] [Full Text] [Related]

  • 37. Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin.
    Degryse E, Acker M, Defreyn G, Bernat A, Maffrand JP, Roitsch C, Courtney M.
    Protein Eng; 1989 Mar 22; 2(6):459-65. PubMed ID: 2710782
    [Abstract] [Full Text] [Related]

  • 38. Kinetics of the inhibition of thrombin by hirudin.
    Stone SR, Hofsteenge J.
    Biochemistry; 1986 Aug 12; 25(16):4622-8. PubMed ID: 3768302
    [Abstract] [Full Text] [Related]

  • 39. Effect of hirudin on the chemotactic properties of alpha-thrombin.
    Morin A, Marchand-Arvier M, Doutremepuich C, Vigneron C.
    Haemostasis; 1991 Aug 12; 21 Suppl 1():32-5. PubMed ID: 1894195
    [Abstract] [Full Text] [Related]

  • 40. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin.
    Braun PJ, Dennis S, Hofsteenge J, Stone SR.
    Biochemistry; 1988 Aug 23; 27(17):6517-22. PubMed ID: 3146347
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.